KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZN) Long-Term Deferred Tax (2016 - 2025)

Astrazeneca has reported Long-Term Deferred Tax over the past 11 years, most recently at $8.0 billion for Q4 2025.

  • Quarterly results put Long-Term Deferred Tax at $8.0 billion for Q4 2025, up 49.6% from a year ago — trailing twelve months through Dec 2025 was $8.0 billion (up 49.6% YoY), and the annual figure for FY2025 was $8.0 billion, up 49.6%.
  • Long-Term Deferred Tax for Q4 2025 was $8.0 billion at Astrazeneca, up from $5.3 billion in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for AZN hit a ceiling of $8.0 billion in Q4 2025 and a floor of $3.3 billion in Q4 2022.
  • Median Long-Term Deferred Tax over the past 5 years was $4.7 billion (2023), compared with a mean of $5.1 billion.
  • Biggest five-year swings in Long-Term Deferred Tax: fell 24.64% in 2022 and later skyrocketed 49.6% in 2025.
  • Astrazeneca's Long-Term Deferred Tax stood at $4.3 billion in 2021, then dropped by 24.64% to $3.3 billion in 2022, then surged by 44.59% to $4.7 billion in 2023, then increased by 13.33% to $5.3 billion in 2024, then soared by 49.6% to $8.0 billion in 2025.
  • The last three reported values for Long-Term Deferred Tax were $8.0 billion (Q4 2025), $5.3 billion (Q4 2024), and $4.7 billion (Q4 2023) per Business Quant data.